← Back to Search

Prescribed Detraining for Atrial Fibrillation (DAF Trial)

N/A
Waitlist Available
Led By James McKinney, MD
Research Sponsored by Cardiology Research UBC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age between 18 and 60
Paroxysmal AF (eligible subjects must have had >1episode of AF within the last 12 months)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up taken at 0, 8, and 32 weeks
Awards & highlights

DAF Trial Summary

This study will examine the effect of detraining as a clinical tool to prevent recurrence of lone paroxysmal atrial fibrillation (AF) and improve quality of life. Persons who engage in endurance activity with AF will be randomly assigned to undergo an 8-week period of detraining or encouraged to maintain their current level of exercise. Participants will receive a handheld device called AliveCor that can record an electrical tracing of the heart rhythm by pressing down with ones' thumbs. The amount of arrhythmia and symptoms will be recorded. The research team hypothesizes that among athletes with lone AF, an 8-week period of detraining will not affect atrial fibrillation recurrence or quality of life.

DAF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

DAF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~taken at 0, 8, and 32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and taken at 0, 8, and 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ratio of atrial fibrillation (AF) episodes
Symptomatic palpitations
Secondary outcome measures
AF symptom severity
Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score
Electric Countershock
+4 more

DAF Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Prescribed DetrainingExperimental Treatment1 Intervention
Detraining period of 8-weeks which is defined as: a 75% decrease in the amount of exercise (from baseline) a 50% decrease in the intensity of exercise as measured in METS (from baseline) Mitchell Classification classes 1A, 2A, 2B of activity are permitted
Group II: Continued Strenuous ExerciseActive Control1 Intervention
Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period

Find a Location

Who is running the clinical trial?

Cardiology Research UBCLead Sponsor
14 Previous Clinical Trials
6,994 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
100 Patients Enrolled for Atrial Fibrillation
James McKinney, MDPrincipal InvestigatorUniversity of British Columbia Department of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~12 spots leftby Mar 2025